Product name as reported
Altabax: adverse event reports filed with FDA
650 reports list it as a suspect or interacting product, 2007–2018.
- 650
- reports as suspect product
- 0% of all reports · about 34 a year
- 0
- reports, 12 months to June 2026
- 0 in the 12 months before
- 6.9%
- marked serious by the reporter
- 57.4% across all reports
- 0%
- record death among outcomes, as reported
- 0 reports · not verified by FDA
650 adverse event reports received by FDA list the product name "Altabax" as reporters wrote it as a suspect or interacting product, from August 2007 to May 2018. A further 34 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 0 reports listed it, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 34 reports a year and 0% of the 20,646,523 reports in the database. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are application site irritation (24.3%), burning sensation (20.8%) and application site pain (12.5%). A report can list several reactions, so shares add to more than 100%; 89 different terms appear across these reports. Application site irritation is recorded in 24.3% of these reports, against 0.1% of all reports in the database.
6.9% of the reports are marked serious by the reporter; 0% record death among the outcomes and 2% record hospitalisation, as reported. 88.5% of the reports came from consumers, and the largest patient age group is 45 to 64 (11.4%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
No report listing Altabax was received in the five years to June 2026; the latest was received in May 2018.
By year received
Reactions recorded in the reports
share of Altabax reports recording the termall reports in the database
- Application site irritation24.3%158
- Burning sensationa burning feeling20.8%135
- Application site pain12.5%81
- Painpain, site not specified11.2%73
- Drug ineffectivethe medicine did not work as expected8.3%54
- Application site erythemaredness where the product was applied6.2%40
- Erythemaskin redness6.2%40
- Pruritusitching5.8%38
- Hypersensitivityan allergic-type reaction5.4%35
- Rashskin rash5.2%34
- Dermatitis contact4.5%29
- Cryingcrying3.2%21
- Skin irritationirritated skin3.2%21
- Blistera blister2.8%18
- Application site pruritusitching where the product was applied2.5%16
- Swellingswelling2.5%16
- Screaming2.3%15
- Thermal burna burn from heat1.8%12
- Drug administration errora mistake in giving the medicine1.5%10
- Skin burning sensationburning skin1.4%9
- Application site reactiona reaction where the product was applied1.1%7
- Ill-defined disordera condition that was not clearly described1.1%7
- Lip swellingswollen lips1.1%7
- Paraesthesiatingling or pins and needles1.1%7
- Cheilitis0.9%6
- Dermatitisinflamed skin0.9%6
- Wound complication0.9%6
- Condition aggravatedthe condition being treated got worse0.8%5
Top 30 of 89 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the share of all reports in the database; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 20,646,523 reports. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 100% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Impetigo | 92 | 14.2% |
| Staphylococcal infection | 35 | 5.4% |
| Wound | 22 | 3.4% |
| Skin infection | 20 | 3.1% |
| Infection | 14 | 2.2% |
| Rash | 9 | 1.4% |
The indication field is filled in by the reporter and is often blank; shares are of all 650 reports.
In context
| Measure | Altabax | All reports |
|---|---|---|
| Reports as suspect product | 650 | 20,646,523 |
| Share of that pool | — | 0% |
| Reports, latest 12 months | 0 | 1,332,454 |
| Marked serious | 6.9% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 0 | 91 |
| Hospitalisation recorded, per 1,000 reports | 20 | 213 |
| Consumer-filed share | 88.5% | 45.8% |
| Top term, share of reports | Application site irritation 24.3% | 0.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Questions about Altabax reports
How many adverse event reports has FDA received for Altabax?
650 reports list Altabax as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 0 of them arrived in the latest 12 months. Another 34 list it only as a concomitant medication.
What reactions are recorded in Altabax reports?
application site irritation (24.3%), burning sensation (20.8%), application site pain (12.5%), pain (11.2%) and drug ineffective (8.3%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Altabax was responsible.
How serious are the reports?
6.9% are marked serious by the reporter. Among the outcomes recorded, 0% of reports include death and 2% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (88.5%), physician (6.9%) and other health professional (3.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Altabax rising?
0 reports in the 12 months to June 2026, and none in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Altabax was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Altabax?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Altabax as a suspect or interacting product; reports listing it only as a concomitant medication (34) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.